Rheumatoid Arthritis
Janet Pope Janetbirdope
4 years 11 months ago
Which Adalimumab biosimilar to use (if any)? The race is on to have 1st Ada or 2nd reimbursed/preferentially listed in US reimbursement plans & dare I say it mandatory switching like in Europe. Abstr#0798 #ACR2020 compares Abrilada & Humira in RA @RheumNow @CRASCRRheum https://t.co/AUcVZnc6Gj
An International Panel Weighs in on RA Studies from Day 1 at ACR
Dr. Jonathan Kay leads a panel of rheumatologists from Dublin, Australia, The Philippines, Boston and Baltimore to talk about several initial abstracts that caught their attention at ACR 2020. Panel participants: Dr. Richard Conway, Dr. David Liew, Dr. Sheila Reyes, Dr. Jeffrey Sparks and Dr. Eric Dein.
sheila RHEUMarampa
4 years 11 months ago
What is your initial csDMARD of choice in pts w/ elderly-onset RA? @RheumNow #ACR20
Eric Dein ejdein1
4 years 11 months ago
Serial RF titers? Abst#0754 from Japan: Pts with RF>45, tracked RF at month 0/4/12 after starting b/tsDMARD. 46/130 had RF decrease titers, had better radiographic remission/DAS28-ESR. Limits: varied Rx, More aggressive Rx w RF decrease grp @RheumNow. #ACR20
Eric Dein ejdein1
4 years 11 months ago
#ACR20 @RheumNow. We think of dichotomy of erosive vs. non-erosive but Abst#0748 shows joint space narrowing precedes erosive disease and requires more attention for early recognition. https://t.co/JLd3xVTlXM
HCQ and QTc Prolongation: Dr David Liew
Dr. David Liew reviews abstracts #0431 presented at the ACR 2020 annual meeting - and shares the results of the Twitter poll he conducted asking when prescribing HCQ, is an EKG routinely ordered either before or doing.
Eric Dein ejdein1
4 years 11 months ago
Will we start getting fine-specificity ACPAs to drive treatment of RA? Abst#0743 shows fs-ACPA (anti-fibrinogen B) predict greater response to ABA+MTX vs MTX alone. #ACR20 @RheumNow. Role of RA antibodies will continue to evolve and guide Rx. https://t.co/pY4mm19Jc7
Meral K. El Ramahi, MD MeralElRamahiMD
4 years 11 months ago
What do you think? The great debate continues... leave your thoughts in the comment section below! #ACR20 @RheumNow @LCalabreseDO @CCalabreseDO https://t.co/KwQX0XoO93
What to do with Subclinical Synovitis? Dr. Jack Cush
Dr. Jack Cush discusses abstract #0481 presented Friday at the ACR 2020 annual meeting.
Safety of JAKs: Venous Thromboembolic Risk: Dr. Kevin Winthrop
OHSU rheumatologist Dr. Kevin Winthrop in Portland looks at two posters -- abstracts #0215 and #0229 presented Friday at ACR 2020.
Dr. John Cush RheumNow
4 years 11 months ago
HCQ Not Associated with QTc Length in SLE and RA Patients: Dr. Janet Pope @Janetbirdope #ACR20
https://t.co/zPIaFIiqr5 https://t.co/Wk8YQpIpo7
Methotrexate Induced Liver Fibrosis: Dr. Sheila Reyes
Dr. Sheila Reyes discusses abstract #0205 presented Friday at the 2020 ACR annual meeting.
sheila RHEUMarampa
4 years 11 months ago
Year in review by @JYazdanyMD ENTRACTE trial: CV safety of TCZ vs. ETN >similar CV events >TCZ grp slightly more infections & GI perforations @RheumNow #ACR20 https://t.co/yBDeHBDB3Z
Meral K. El Ramahi, MD MeralElRamahiMD
4 years 11 months ago
Abst#0194 at #ACR20 showed that significant symptoms of depression in RA are more frequent than depression diagnosed clinically, suggesting that depression may go undiagnosed and that symptoms of depression predicted mortality in RA patients! @RheumNow https://t.co/GqwXNB45y2
sheila RHEUMarampa
4 years 11 months ago
ACPA+ and subclinical synovitis does not automatically mean developing to RA.
Interesting work by Cleo Rogier et al. Something to consider in pts w/arthralgias & when to start csDMARDs @RheumNow #ACR20 Abstr#481 #ACRbest https://t.co/q3vIITmtq2
Poster Hall